Major benefits from cholesterol-lowering in patients with diabetes

Lancet

Volumn 361, Issue 9374, 2003, Pages 2000-2001

  Lindholm, Lars H ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN;

ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE COURSE; FOLLOW UP; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; REDUCTION; REVASCULARIZATION; RISK FACTOR; UNITED KINGDOM;

EID: 0037502669     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13672-0     Document Type: Note

References (8)

1. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 288:2002;2998-3007.
2. Sever P.S., Dahlöf B., Poulter N.R. Prevention of coronary and stroke events with atorvastatin in hypertensive subjects who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158.
3. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type-2 diabetes. N Engl J Med. 348:2003;383-393.
4. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 25:2002;S33-S49.
5. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
6. McIntosh A, Hutchinson A, Feder G, et al. Clinical guidelines and evidence review for type 2 diabetes: lipids management. 2002: http://www.shef.ac.uk/guidelines (accessed May 9, 2003).
7. Management of dyslipidemia in adults with diabetes. Diabetes Care. 26:2003;S83-S86.
8. Lindholm L.H., Ibsen H., Dahlöf B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;1004-1010.